OncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017

SAN DIEGO, Oct. 11, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present updated clinical data from its phase 2 Investigator Sponsored Trial assessing the combination of OncoSec's investigational therapy, ImmunoPulse^® IL-12 (intratumoral pIL-12 [tavokinogene telseplasmid or "tavo"] with electroporation), and the approved anti-PD-1 therapy pembrolizumab, in patients with unresectable metastatic melanoma. The late-breaking poster presentation will occur at the upcoming Society for Immunotherapy of Cancer ("SITC") 32^nd Annual Meeting to be held on November 8-12, 2017, in National Harbor, MD. In addition, OncoSec will present preclinical data from its novel multi-gene expression platform termed PIIM (Polycistronic Interleukin-12 Immune Modulator) as a poster presentation at the same meeting.

"We are pleased that the Society for Immunotherapy of Cancer will highlight updated clinical data from our phase 2 study that led us to initiate our global, open-label, registration directed phase 2b clinical trial, PISCES/KEYNOTE-695, which will evaluate the combination of ImmunoPulse IL-12 and pembrolizumab in metastatic melanoma patients who are progressing or have progressed on anti-PD-1," said Punit Dhillon, CEO and President at OncoSec. "We remain committed to excelling in scientific innovation and clinical development and look forward to sharing data from our recently initiated study in mid-2018."

The late-breaking poster presentation details are as follows:

Title: Clinical and biomarker analyses of a phase II study of intratumoral tavokinogene telseplasmid (pIL-12) plus pembrolizumab in stage III/IV melanoma patients predicted to not respond to anti-PD-1

Poster Number: P524

Lead Author: Alain Algazi, MD, Associate Professor, Department of Medicine (Hematology/Oncology), UCSF

Date and Time: Saturday, November 11^th, 12:30-2:00 p.m. and 6:30-8:00 p.m.

Location: Gaylord National Resort & Convention Center

For more information about this trial, please visit:
https://clinicaltrials.gov/ct2/show/NCT02493361?term=pIL-12&rank=3

The poster presentation details are as follows:

Title: Intratumoral administration of a multigene construct by electroporation can effectively modulate anti-tumor response in a murine B16.F10 model

Poster Number: P403 

Lead Author: Shawna Shirley, Ph.D., Senior Scientist, OncoSec

Session Title: Oncolytic Viruses and Intratumoral Therapies

Date and Time: Friday, November 10^th, 12:30-2:00 p.m. and 6:30-8:00 p.m.

Location: Gaylord National Resort & Convention Center

Per SITC guidelines, abstracts are embargoed until 8:00 a.m. EST on November 7, 2017.  To view abstracts, please visit the SITC website at https://www.sitcancer.org/2017/abstracts/info.

ImmunoPulse® is a registered trademark of OncoSec Medical Incorporated, San Diego, CA, USA.

About the SITC Annual Meeting
The Society for Immunotherapy of Cancer (SITC) is a non-profit medical professional society of influential scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.  Currently, SITC has nearly 1,600 members representing 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer. The 32^nd SITC Annual Meeting & Associated Programs will take place November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, MD. For more information, please go to http://www.sitcancer.org/2017.

About PISCES (Anti-PD-1 IL-12 Stage III/IV Combination Electroporation Study)
PISCES is a global, multicenter phase 2b, open-label trial of intratumoral plasma encoded IL-12 (tavokinogene telseplasmid or "tavo") delivered by electroporation in combination with intravenous pembrolizumab in patients with stage III/IV melanoma who have progressed or are progressing on either pembrolizumab or nivolumab treatment. The Simon 2-stage study of intratumoral tavo plus electroporation in combination with pembrolizumab will enroll approximately 48 patients with histological diagnosis of melanoma with progressive locally advanced or metastatic disease defined as Stage III or Stage IV. The primary endpoint will be the Best Overall Response Rate (BORR).

About OncoSec Medical Incorporated:
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase 1 and 2 clinical trials, ImmunoPulse® IL-12 (delivering pIL-12 referred to as tavokinogene telseplasmid or "tavo") has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response. OncoSec's lead program with tavo is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus with PISCES is on the significant unmet medical need in patients with melanoma who are refractory or have relapsed on anti-PD-1 therapies. In addition to tavo, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform. For more information, please visit www.oncosec.com.

CONTACT:

Investor Relations 
OncoSec Medical Incorporated
855-662-6732
[email protected]

Media Relations 
OncoSec Medical Incorporated
855-662-6732
[email protected]

SOURCE OncoSec Medical Incorporated

Related Links

http://www.oncosec.com